APA način citiranja (7. izdanje)

Murphy, F., Church, D., Medley, L., Davies, J., Breen, D., Clelland, C., . . . Talbot, D. (2011). PHASE II TRIAL OF ERLOTINIB AS FIRST-LINE THERAPY IN NON-SMALL CELL LUNG CANCER OVER-EXPRESSING EGFR.

Čikaški stil citiranja (17. izdanje)

Murphy, F., et al. PHASE II TRIAL OF ERLOTINIB AS FIRST-LINE THERAPY IN NON-SMALL CELL LUNG CANCER OVER-EXPRESSING EGFR. 2011.

MLA način citiranja (9. izdanje)

Murphy, F., et al. PHASE II TRIAL OF ERLOTINIB AS FIRST-LINE THERAPY IN NON-SMALL CELL LUNG CANCER OVER-EXPRESSING EGFR. 2011.